Sep 26, 2024 7:00 am EDT Eyenovia Announces Launch and Commercial Availability of Clobetasol Propionate Ophthalmic Suspension 0.05% for Post-Operative Inflammation and Pain Following Ocular Surgery
Sep 5, 2024 7:00 am EDT Eyenovia Announces Taiwan Export License Approval to Commence Shipment of Clobetasol Propionate Ophthalmic Suspension (0.05%) to the U.S.
Sep 3, 2024 7:00 am EDT Eyenovia Announces Appointment of Experienced Finance and Accounting Executive Andrew Jones as Chief Financial Officer
Aug 13, 2024 7:00 am EDT Eyenovia to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
Aug 12, 2024 4:05 pm EDT Eyenovia Reports Second Quarter 2024 Financial Results and Provides Corporate Update